Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4940-4948

  Benimetskaya, Luba ^a   Ayyanar, Kanyalakshmi ^a   Kornblum, Noah ^a   Castanotto, Daniela ^b   Rossi, John ^b   Wu, Sijian ^a   Lai, Johnathan ^a   Brown, Bob D ^c   Popova, Natalia ^a   Miller, Paul ^d   McMicken, Marilyn ^e   Chen, Yin ^e   Stein, C A ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Genta Inc   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e CytoGenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; CYTOCHROME C; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; RNA; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MITOCHONDRION; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN TARGETING; SKIN NECROSIS; START CODON; TISSUE CULTURE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CYTOCHROMES C; DNA, ANTISENSE; DOWN-REGULATION; GENE SILENCING; HUMANS; MELANOMA; MICE; MICE, INBRED ICR; MICE, SCID; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; THIONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748349447     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1002     Document Type: Article

References (41)

1. Saenz-Santamaria M, Reed J, McNutt N. Immunohistochemical expression of Bcl-2 in melanoma and intradermal nevi. J Cutan Pathol 1994;21:393-7.
2. Plettenberg A, Ballaun C, Rammer J. Human melanocytes and melanoma cells constitutively expresss the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 1995;146:651-9.
3. Cerroni L, Soyer H, Kerl H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.
4. Miyashita T, Reed J. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
5. Kamesaki S, Kamesaki H, Jorgensen T. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on event subsequent to topoisomeralse II-induced DNA strand breaks and their repair. Cancer Res 1993;53:4251-6.
6. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995;55:3902-7.
7. Raffo A, Lai J, Miller P. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004;10:3195-206.
8. Dorai T, Goluboff ET, Olsson CA, et al. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997;17:3307-12.
9. Klasa RJ, Gillum A, Klem R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
10. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
11. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet 2000;356:1728-33.
12. Benimetskaya I, Lai J, Khvorova A, et al. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res 2004;10:8371-9.
13. Lai J, Benimetskaya L, Khvorova A, et al. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol Cancer Ther 2005;4:305-15.
14. Kirkwood J, Bedikian A, Milllward M. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (abstr). Proc Am Soc Clin Oncol 2005;23:711-1.
15. Gekeler V, Gimmnich P, Hofmann H-P, et al. G3139 and other CpG-containing immuno-stimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 2006;16:83-93.
16. Lai J, Tan W, Benimetskaya L, et al. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A 2006;103:7494-9.
17. Siskind L, Kolesnick R, Colombini M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J Biol Chem 2002;277:26796-803.
18. Wacheck V, Losert D, Gunsberg P, et al. Small interfering RNA targeting Bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400.
19. Chen Y, McMicken H. Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector. Gene Ther 2003;2003:1776-80.
20. Chen Y, Ji Y-J, Roxby R, et al. In vivo expression of single-stranded DNA in mammalian cells with DNA enzyme sequences targeted to c-raf. Antisense Nucleic Acid Drug Dev 2000;10:415-22.
21. Castanotto D, Scherer L. Down-regulation of cellular genes by PCR cassettes expressing short interfering RNAs. Methods Enzymol 2005;392:173-85.
22. Benimetskaya L, Miller P, Benimetsky S, et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-α (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001;60:1296-307.
23. Benimetskaya L, Wittenberger T, Stein CA, et al. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-β and -γ. Clin Cancer Res 2004;10:3678-88.
24. Castanotto D, Li H, Rossi J. Functional siRNA expression from transfected PCR products. RNA 2002;8:1454-60.
25. Zou H, Henzel W, Liu H, et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-13.
26. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
27. Zou H, Li Y, Wang H. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
28. Datta H, Glaser P. Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination. Nucleic Acids Res 2001;29:5140-7.
29. McMicken H, Bates P, Chen Y. Antiproliferative activity of G-quartet-containing oligonucleotides generated by a novel single-stranded DNA expression system. Cancer Gene Ther 2003;10:867-9.
30. Bates P, Kahlon J, Thomas S. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-77.
31. Xu X, Hamhouyia F, Thomas S. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276:43221-30.
32. Amarguioui M, Rossi J, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005;579:5974-81.
33. Ito M, Kawano K, Miyagishi M, et al. Genomewide application of RNAi to the discovery of potencial drug targets. FEBS Lett 2005;579 5988-95.
34. Scherer L, Yildiz Y, Kim J, et al. Rapid assessment of anti-HIV siRNA efficacy using the PCR-derived pol III shRNA cassettes. Mol Ther 2004;10:597-603.
35. Sandy P, Ventura A, Jacks T. Mammalian RNAi: a practical guide. Biotechniques 2005;39:215-24.
36. Lu P, Xie F, Woodle M. In vivo application of RNA interference: from functonal genomics to therapeutics Adv Genet 2005;54:117-42.
37. Elbashir S, Harborth J, Lendeckel W. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411 494-8.
38. Iervolino A, Trisciuoglio D, Ribatti D. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNAstabilization and HIF-1 mediated transcriptional activity. FASEB J 2002;16:1453-6.
39. Biroccio A, Candiloro A, Mottolese M. Bcl-2 over expression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line FASEB J 2000;14:652-60.
40. Trisciuoglio D, Desideri M, Ciuffreda L, et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005;205:414-21.
41. Karl E, Warner K, Zeitim B. Bcl-2 acts in a pro-angiogenic signaling pathway through nuclear factor-kB and CXC chemokines. Cancer Res 2005;65:5063-9.